Genomics vs. Cancer | GenomeWeb

Genomics vs. Cancer

Premium

While cancer research never stays still for long, the past year saw major shifts in the application of genomic tools to the field. Last fall, The Cancer Genome Atlas published initial results of its first programs in glioblastoma multiforme; around the same time, the Tumor Sequencing Project Consortium reported its early findings from an international study of lung adenocarcinoma. On the technology side, next-gen sequencing continues to revolutionize the field as it has radically altered the types of questions scientists can ask of precious tumor samples.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.